Condition
Drug Combination
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04080895Phase 1Terminated
Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
NCT03995862Completed
Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region
NCT02696954Phase 1Terminated
Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects
NCT02568098Phase 1CompletedPrimary
Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects
Showing all 4 trials